This study is testing whether a lower dose of a medicine called cyclophosphamide (25 mg per kg), given after an allogeneic stem cell transplant, can reduce serious side effects and improve outcomes. We are enrolling people who are receiving a reduced-intensity or non-myeloablative (less intensive) stem cell transplant. We will follow participants for one year after their transplant to see if they stay free from severe graft-versus-host disease (GVHD), cancer relapse, or death. We will also look at overall survival, rates of GVHD, infections, donor cell recovery, and other side effects.

You must attend all scheduled study visits, tell the study doctor about all medications you are taking (including over-the-counter medicines), and let the study team know how you are feeling. Before joining the study, you will have routine health checks. These include breathing tests (called pulmonary function tests, or PFTs) to see how well your lungs work, and a heart scan (MUGA scan or echocardiogram) to see how well your heart is pumping. As part of this study, you will be given a low dose of cyclophosphamide (25 mg/kg) on day +3 and +4 after your stem cell transplant. You will be carefully monitored for any side effects, and the study team will evaluate your risk for graft-versus-host disease (GVHD) and disease relapse.

This project will be an 18-month dietary intervention of prune consumption during the late perimenopausal period of the menopause transition investigating if prune intake can slow down the rapid period of bone loss (bone mineral density) that occurs in the late transmenopause. The study will also investigate the effects of prune intake on inflammation, gut permeability, gut microbiome, and bone strength and geometry. Women transitioning into menopause will be randomized to either a group that will consume 6 prunes/day or to a no-prune group that will avoid prunes for the entire duration of the 18-month intervention. Both groups will consume calcium and vitamin D supplements daily. Study procedures will include collection of blood, urine, and stool samples, bone and body composition scans, completion of health-related questionnaires, exercise records, and daily compliance logs.

Participants will be asked to consume calcium and vitamin D supplements daily for 18 months and will be randomized into either a group that will be asked to consume 6 prunes daily for 18 months, or a control group that will be asked to avoid prunes and similar fruits (for example, blueberries, blackberries, pomegranates) for 18 months. There will be 10 in-person visits and 13 virtual visits (Zoom calls). In-person visits include questionnaires, blood draws, and bone and body composition scans. The study also involves urine and stool sampling.

$300

This study examines whether night-shift healthcare workers who experience greater differences in their sleep timing between days off and after night shifts also report poorer sleep quality. Participants will complete a brief anonymous online survey about their typical sleep patterns and overall sleep quality.

Complete a one-time anonymous online survey (5-10 minutes) about sleep patterns and sleep quality. Survey includes questions about typical sleep times on days off and after night shifts, plus brief demographics and work information.

This study is to see if patients with clinical stage I-III HER2+ breast cancer who achieve a pCR after neoadjuvant chemotherapy with HER2 blockade and receive a total of 6 months of HER2 blockade in the combined neoadjuvant + adjuvant (neo/adjuvant) setting will NOT have inferior (RFS) compared to patients who receive the standard total of 1 year of HER2 blockade.

Participants will get the HER2-targeted medication trastuzumab (with or without pertuzumab) for up to 51 weeks (approximately 12 months), or they will get the HER2-targeted medication trastuzumab (with or without pertuzumab) for up to 27 weeks (approximately 6 months). After participant finishes study treatment, your doctor will continue to follow your condition every 6 months for 5 years and watch for side effects or cancer coming back. Participants will see your doctor for 5 years after treatment. After that, every year for a total of 10 years after being enrolled on the study.

This is a usability study that will evaluate how allied health, education and technology professionals perceive a new virtual therapy environment designed for children with autism spectrum disorder. Participants will experience a guided session using a virtual reality headset and then complete questionnaires about usability, immersion, and any discomfort. The goal is to improve the tool before it is used in clinical settings.

There will be only one on-site meeting with one hour of duration. Participants will take part in an 25 minutes immersive experience in a virtual environment and complete one questionnaire before, and four questionnaires after the experience.

$30 Amazon gift card

The purpose of this voluntary research study is to test the effectiveness of the Positive Affect Intervention Program in reducing mental health symptoms for families experiencing financial hardship.

In this study, you and your child will attend some virtual study visits over 8 months. At each visit, you will complete some interviews, questionnaires, and discussion tasks with your child. You will be randomly assigned to either an 8-session prevention program or to receive weekly educational materials to read. You and your child will also be asked to complete some short daily phone surveys.

320 dollars

This study will see if participants who have the addition of saruparib to their treatment will have a longer time period before/if their cancer spreads.

Before participating in the trial, p[otential; participants will need to sign a consent form to have their tumor tested for the BRCA mutation. If the participants have this mutation in their tumor, they will be invited to participate in this trial. While you are receiving treatment you will need to come to the clinic on certain days for treatment, getting safety assessments, collection of blood samples and to see how you are feeling. You will come to the clinic every four weeks. The treatment will last for 24 months

This study is looking at how Mim8 works in people with hemophilia A, who either have inhibitors or do not have inhibitors. Mim8 is a new medicine that will be used to avoid bleeding episodes. Mim8 will be injected under the skin with a thin needle for up to 262 injections; the number of injections depends on how often injections are given.

Mim8 will be injected under the skin with a thin needle either once a week, once every two weeks or once a month. The study will last for up to 2.5 years. There will be fourteen in person visits and up to 2 phone visits. Completion of diary and PRO questionnaire.

$75 per visit up to $1050 (14 visits) to cover travel expenses

This study is comparing Pembrolizumab in combination with Sacituzumab Govitecan vs. standard treatment for individuals who have drug resistant advanced urolethial cancer

Participants will need to come to the clinic to meet with the study team and to sign a consent form. Once it has been determined that it is safe for you to participate, you will come into the clinic for treatment every 21 days, or depending upon the treatment arm you are assigned. You will continue to come into the clinic for treatment until the medication stops working, you no longer want to participate in the study or the document feels it is not safe for you to continue. You will be followed for up to five years to see how you are doing.

As more people around the world are getting older, there’s a growing need for homes that help seniors live independently while staying healthy, safe, and comfortable. This project explores how smart home technologies—like non-intrusive health monitors and privacy-respecting systems—can support aging in place. Instead of building these homes, the study gathers insights through surveys of older adults living independently to understand their needs, preferences, and concerns. Digital design tools (known as Building Information Modeling, or BIM) and Virtual Reality (VR) will be used to create simulated smart home environments based on the survey responses. These simulations allow researchers and participants to visualize and interact with potential home designs, helping older adults get familiar with future living spaces and stay socially connected through virtual activities that may reduce loneliness and support cognitive health. Artificial Intelligence (AI) is explored as a potential tool for enhancing smart home systems—such as monitoring health, detecting early signs of concern, and supporting memory and social interaction. While the homes are not being built, the project evaluates how these technologies might impact well-being, healthcare costs, and home durability. Findings will be shared through research papers, workshops, and online events to support the development of smarter, more supportive living environments for older adults.

Participants will be involved by taking a survey. We are still in the process of either choosing StudyFinder or Cloud Research. This study is designed to learn how older adults feel about smart home technologies that are meant to help them live safely and independently. Participants will be asked to complete a survey that includes questions about their comfort, safety, privacy, and interest in using devices like motion sensors, voice assistants, and virtual reality tools in their homes.

The purpose of this study is to evaluate the effect of lifetime self-report physical activity behavior on current cognitive and mental health status in populations of different ages through the lifespan. We will use a digital survey to obtain physical activity behavior reports, including intensity, duration, and physical activity type during several periods of each participant's life, and utilize online cognitive tests and mental health questionnaires to obtain current mental health and cognitive capacity.

Participants will complete an anonymous online survey that asks about their physical activity trends across their lifetime and their current mental health status. The survey will also direct the participants to several brief online cognitive tests. The survey will take approximately 20 minutes to complete. Participants who complete the survey will have the opportunity to fill out a separate form to be entered (via email address) into a drawing to win a $100 prize.

$100 compensation drawing entry

The objective of this study is to understand how university students use generative AI tools like ChatGPT, Gemini, and others when engaging in writing tasks, whether personally (e.g., writing emails) or academically (e.g., completing assignments), and how their cognitive processes work with these tools.

This study aims to understand how university students interact with generative AI tools like ChatGPT, Gemini, and others in writing tasks, both personally (e.g., writing emails, cover letter) and academically (e.g., completing assignments). We will conduct 1) brief demographic survey 2) interviews and 3) think-aloud sessions with students to understand how generative AI tools are used in writing.

$40

This is a quantitative study investigating the relationship between family functionality, substance use, and mental health among a population of emerging adults.

You will take a brief survey.

This is a Phase 2b clinical research study, which is investigating the use of 5-Aminolevulinic Acid (5-ALA) combined with a Low-Intensity Diffuse Ultrasound (LIDU) system for Sonodynamic Therapy (SDT) in patients with newly diagnosed glioblastoma. LIDU is the name of the investigational SDT device developed by Alpheus Medical. SDT includes the combination of a sonosensitizing drug, also known as a sonosensitizer, that will only be absorbed by tumor cells, and ultrasound to activate the sonosensitizer and cause damage to the tumor cells. The SDT tested in this study includes the oral drug 5-Aminolevulinic Acid (5-ALA) as an investigational sonosensitizer. This investigational treatment is being tested as a potential treatment for your cancer, SDT has been shown in previous cell and animal studies to potentially have an anti-cancer effect.

In this research study there will be two treatment groups. One treatment group will receive standard of care maintenance temozolomide with 5-ALA + SDT, you will have a 50% of receiving this treatment group. The other treatment group wll receive standard of care maintenance temozolomide with placebo, an oral solution that will look like and taste like 5-ALA but will have no active ingredients in it, and sham SDT, a program will be run on the SDT device that will look and sound the same, but will not deliver ultrasound, you will have a 50% chance of receiving this treatment group. If you are eligible for the study, and agree to participate you will be randomized, like the flip of a coin, to one of the two treatment groups, neither you nor your doctors will know which treatment group you have been assigned.

This trial is designed for patients who are newly diagnosed with multiple myeloma (MM) but who do not want or cannot have an autologous stem cell transplant. Teclistamab and talquetamab have been used alone along with other drugs in the treatment of MM. this study hopes to add either drug to a standard treatment for MM at time of diagnosis to see how effective it is in keeping the MM quiet conpared to standard treatment alone.

Participants must be willing to come to all clinic study visits. The first cycle of treatment the participant will be hospitalized to make sure they do not have any side effects. You will be treated every four weeks as an outpatient until the treatment no longer works. You should tell your study team all side effects you feel and all medication you are taking.

$54.00 per completed visit. A caregiver may receive compensation of the same amount.

The purpose of this study is to investigate the effects of replacing snacks high in saturated fats and added sugars with pecans on blood sugar control, heart health and diet quality in individuals with prediabetes. Participants will be randomized into one of two groups. Group 1 will consume 1.5 oz of pecans per day in place of normally consumed snacks high in saturated fat and added sugars for 16 weeks. Group 2 will be asked to continue consuming their current diet for 16 weeks. Measures will be taken to evaluate blood sugar, heart health and dietary intake at the beginning and 16 weeks later.

• The total time commitment for this study is approximately 4 months. It may take up to 7 months to complete the study from the time that you do the clinic screening visit. • During the study, we will ask you to consume 1.5 oz of pecans per day for 16 weeks, or to use provided gift cards to purchase and consume your usual snacks/diet. • You will be asked to come to the Penn State Research Kitchen on campus once a month for 16 weeks to pick up your pecans or gift cards. • We will draw blood from you several times during the study, once at screening, and on two consecutive days at the start and end of the study (total 5 times). • At the start and end of the study, we will also measure your blood pressure and perform non-invasive tests of artery health. • You will also be asked to wear a continuous glucose monitor (CGM) for 14 days—7 days before the first testing visit and 7 days at the end of the study. The CGM is a small sensor worn on your arm that measures your blood sugar every 15 minutes. You will need to attend a non-fasting visit to have the CGM fitted (2 visits total). • At the start and end of the study, we will ask you to collect 12 saliva samples over two days at home. • At the start and end of the study, we will collect a small hair sample from the back of your head. • You will also be asked to collect a stool sample at the beginning and end of the study (2 total). • Compensation for this study is up to $150

150